Monthly Schizophrenia Treatment Cost 20%-30% Lower With First-Generation Drug
This article was originally published in The Pink Sheet Daily
Catie research published in the American Journal of Psychiatry shows that treatment with older drugs may be less expensive but just as effective.
You may also be interested in...
Forthcoming cost-effectiveness analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness study could prove to be a boon for Zyprexa because of reduced hospitalization with Lilly’s atypical antipsychotic.
U.S. sales of the antipsychotic fell 10% in the third quarter; CATIE trial results will not boost Zyprexa sales "overnight," COO Lechleiter says.
CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.